In a double-blind study versus placebo, the serotonergic agent m- chlorophenylpiperazine (mCPP) was administered to 20 healthy control subjects and 19 migraineurs to investigate the ability of mCPP (0.5 mg/kg) to induce typical migraine attacks. In the following 24-hours there were more migraines after mCPP than after placebo in both groups. These findings are consistent with involvement of 5HT(2B,2C,1A) receptor subtypes in the pathophysiology of migraine.
|Number of pages||4|
|Publication status||Published - Jul 12 2000|
ASJC Scopus subject areas